Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Olivia CampagneDonald E Mager

Abstract

Purpose: Flotetuzumab (MGD006 or S80880) is a bispecific molecule that recognizes CD3 and CD123 membrane proteins, redirecting T cells to kill CD123-expressing cells for the treatment of acute myeloid leukemia. In this study, we developed a mathematical model to characterize MGD006 exposure-response relationships and to assess the impact of its immunogenicity in cynomolgus monkeys.Experimental Design: Thirty-two animals received multiple escalating doses (100-300-600-1,000 ng/kg/day) via intravenous infusion continuously 4 days a week. The model reflects sequential binding of MGD006 to CD3 and CD123 receptors. Formation of the MGD006/CD3 complex was connected to total T cells undergoing trafficking, whereas the formation of the trimolecular complex results in T-cell activation and clonal expansion. Activated T cells were used to drive the peripheral depletion of CD123-positive cells. Anti-drug antibody development was linked to MGD006 disposition as an elimination pathway. Model validation was tested by predicting the activity of MGD006 in eight monkeys receiving continuous 7-day infusions.Results: MGD006 disposition and total T-cell and CD123-positive cell profiles were well characterized. Anti-drug antibody development led to...Continue Reading

References

Jan 1, 1988·Annual Review of Immunology·H CleversC Terhorst
Oct 1, 1994·Clinical Pharmacology and Therapeutics·W J Jusko, H C Ko
Apr 5, 1996·Science·M A Nowak, C R Bangham
Feb 17, 2001·Journal of Applied Toxicology : JAT·K H DiehlUNKNOWN European Federation of Pharmaceutical Industries Association and European Centre for the Validation of Alternative Methods
May 10, 2002·Journal of Pharmacokinetics and Pharmacodynamics·D E Mager, W J Jusko
Apr 26, 2003·Journal of Theoretical Biology·Rustom AntiaRafi Ahmed
Oct 11, 2003·Journal of Clinical Pharmacology·Donald E MagerWilliam J Jusko
Jan 22, 2005·Nature Reviews. Immunology·Rustom AntiaRafi Ahmed
Mar 1, 2005·Basic & Clinical Pharmacology & Toxicology·Mats O KarlssonRujia Xie
Oct 11, 2005·Drug Discovery Today·Evelyn WolfPatrick A Baeuerle
Nov 28, 2006·Lancet·Elihu Estey, Hartmut Döhner
Apr 5, 2008·Clinical Pharmacology and Therapeutics·D E Mager, W J Jusko
Jun 11, 2009·Cancer Research·Patrick A Baeuerle, Carsten Reinhardt
Aug 4, 2009·The AAPS Journal·Radojka M Savic, Mats O Karlsson
Jul 30, 2010·Journal of Pharmacokinetics and Pharmacodynamics·Leonid Gibiansky, Ekaterina Gibiansky
Feb 9, 2011·The AAPS Journal·Martin BergstrandMats O Karlsson
Sep 4, 2012·Pharmacology & Therapeutics·Dirk NagorsenRalf Bargou
Jan 10, 2013·Clinical Pharmacokinetics·Miroslav DostalekManoranjenni Chetty
Jan 15, 2013·Journal of Theoretical Biology·Rob J De Boer, Alan S Perelson
Oct 17, 2014·American Journal of Hematology·Elihu H Estey
Mar 3, 2015·Drug Discovery Today·Roland E Kontermann, Ulrich Brinkmann
Dec 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Megan Brafford May, Ashley Glode
Jan 29, 2016·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Kapil GadkarSaroja Ramanujan
Jun 7, 2016·Nature Reviews. Immunology·Maike de la RocheGillian M Griffiths

❮ Previous
Next ❯

Citations

Aug 21, 2018·Current Opinion in Oncology·Juan MontoroManuel Guerreiro
Jun 28, 2019·Cardiovascular & Hematological Disorders Drug Targets·Mingyue ShiMingyi Chen
Jun 21, 2019·Science Translational Medicine·Alison CrawfordJessica R Kirshner
Jul 10, 2019·Therapeutic Drug Monitoring·Josée Golay, Mario Regazzi
Jun 25, 2020·Clinical Pharmacology and Therapeutics·Alison Betts, Piet H van der Graaf
Aug 2, 2020·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·R Yu KiselevaC F Greineder
Oct 4, 2018·Current Hematologic Malignancy Reports·Daniel G Guy, Geoffrey L Uy
Oct 23, 2020·Physics in Medicine and Biology·Damijan Valentinuzzi, Robert Jeraj
Jan 14, 2021·Current Oncology Reports·Shannon E Conneely, Alexandra M Stevens
Oct 12, 2020·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ling SongTianyan Zhou
Sep 4, 2020·Clinical and Translational Science·Peter N MorcosChi-Chung Li
May 5, 2021·Journal of Hematology & Oncology·Zheng TianXin Wang
May 18, 2021·Leukemia & Lymphoma·Mrinal M PatnaikNaveen Pemmaraju
May 25, 2021·Frontiers in Immunology·Jiabing MaCheng Qian
Jul 10, 2021·Nature Reviews. Urology·Philipp WolfToni Cathomen
Jun 25, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Arthur J Van De VyverAntje-Christine Walz

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.